Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.55 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.55 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7323841 | 0.91 | KLK7 (0.63) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL13430768 | 0.91 | SIRT2 (0.64) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL30043940 | 0.91 | SIRT2 (0.64) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL22043592 | 0.91 | SIRT2 (0.56) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL13599684 | 0.90 | MAPT (0.57) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL17039826 | 0.90 | FOLH1 (0.60) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL5309738 | 0.90 | MAPT (0.53) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL8246040 | 0.90 | MAPT (0.53) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL8245686 | 0.90 | MAPT (0.53) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL13154756 | 0.89 | SIRT2 (0.54) | KLK7KLK5SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093235-B2 | Macrocyclic compounds which stabilize G-Quadruplex DNA and RNA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090156627-A1 | THERAPEUTIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-06-18 | — | — | US | disclosed |
| WO-2009018549-A1 | THERAPEUTIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156627-A1 | THERAPEUTIC COMPOUNDS | TOP2B, DDB1, RECQL | KLK7 4616/4885KLK5 4764/4885SIRT2 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.